APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation: COMMENTdoi:10.1111/jth.15356Michael J. KovacsDepartment of Medicine Western University London ON CanadaAlejandro Lazo-Langner...
The activated partial thromboplastin time (aPTT) test has been used to monitor UFH therapy for decades in Korea, but its results can be affected by numerous variables. We established an aPTT heparin therapeutic range (HTR) corresponding to therapeutic anti-Xa levels for continuous intravenous UFH ...
241 RISK OF SUPRATHERAPEUTIC APTT IN THE ABSENCE OF AN INITIAL UNFRACTIONATED HEPARIN BOLUS F Bonenfant, B Cossette, V Nault, M Turgeon, M Paulin, D Echenberg, P Charron, M Lépine, T Fayad, P Farand Sherbrooke, Québec BACKGROUND: Unfractionated heparin (UFH) is an anticoag- ulant ...
We evaluated the effects on anticoagulant levels before (group A) and after (group B) the introduction of a heparin nomogram in consecutive AMI-patients, receiving thrombolytic therapy and adjunctive heparin treatment. The target activated partial thromboplastin time (aPTT) was defined as 60–90 s....
Therapeutic ranges and laboratory monitoring of heparin using the APTTMaeder, Ellena M.Giannoutsos, JohnVanniasinkam, ThiruFavaloro, Emmanuel J.Australian Journal of Medical Science
APTTHeparinPregnancyIn pregnant women, activated partial thromboplastin time (APTT) does not precisely reflect the anticoagulant effect of a therapeutic dose of heparin. However, the measurement of anti-Xa activity can be used to monitor the anticoagulant effect of heparin, since the plasma ...
APTTanticoagulantsheparinhealthcare costsMonitoring of unfractionated heparin therapy by activated partial thromboplastin time using the ex vivo method for determining the heparin therapeutic range (HTR) is the standard of practice. Many extrinsic and intrinsic factors influence accuracy of the HTR. This ...
C0591: Establishing APTT Therapeutic Range for Patients Receiving Standard Unfractioned HeparinThe efficiency of human recombinant erythropoietin in alleviating anaemia in haemodialyzed patients has been well documented. However, the effects of rHuEPO therapy in correction of antioxidant capacity are not ...
Impact of COVID-19 on monitoring of therapeutic unfractionated heparin. J. Thromb. Thrombolysis 2021, 51, 827–829. [Google Scholar] [CrossRef] Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and ...